PaTHway Phase 3 Trial Analysis
Program Status and Next Steps
0
Two Open-Label Extension trials continuing
57 of 59 patients remain in PaTH Forward Trial after two years
All 79 patients who completed the blinded period continue in the PaTHway Trial
Engage with regulatory authorities regarding registration plans for US and EU
Anticipated NDA submission to FDA during Q3, 2022
Anticipated MAA submission to EMA during Q4, 2022
Continue adult TransCon PTH trial in China*
Japan Phase 3 top-line data expected in Q3, 2022
Plan to initiate pediatric TransCon PTH trial in Q4, 2022
*In development in Greater China through strategic investment in VISEN
27 Pharmaceuticals.
TransCon PTH is an investigational product candidate.
For investor communication only.
Not for use in product promotion. Not for further distribution.
ратнішач
TRIAL
ascendis
pharmaView entire presentation